Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHILLES study of prolonged-release versus immediate-release mexiletine in non-dystrophic myotonias
2024-514970-27-00Phase 3Authorised
- Sponsor
- Lupin Atlantis Holdings
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of fresolimumab and mexiletine in non-dystrophic myotonia (NDM) (2 arms), sponsored by Lupin Atlantis Holdings. Primary endpoint: Incidence of treatment-emergent adverse events and discontinuation. Planned start Sep 2025; status: authorised.
02
Drugs
fresolimumabmexiletine
03
Conditions
non-dystrophic myotonia (NDM)
Beyond the preview
Go deeper on 2024-514970-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514970-27-00.